FDA ad comm favors Zevra’s Niemann-Pick drug

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning! Today, we discuss the maneuverings of two interesting women in biotech: Verily alum Amy Abernethy and 23andMe CEO Anne Wojcicki. Also, we explore the dangers of off-brand GLP-1s, and see FDA advisers vote in favor of a Niemann-Pick drug.

The danger of alternate GLP-1 sources

Shortages of GLP-1 drugs have prompted patients to rely on risky sources for these medicines, like illegal online pharmacies that don’t require prescriptions. A new JAMA paper found that semaglutide from such sites can be contaminated with bacteria, and contain far more of the drug than labeled.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In